Non‑synonymous polymorphisms in the HRC and ADRB1 genes may be associated with all‑cause death in patients with

Tanise Machado Telles1, Bruna Miers May2, Mauricio Pimentel2

  • 1Laboratory of Human Molecular Genetics, Lutheran University of Brazil, Canoas, Rio Grande do Sul 92425-900, Brazil.

PubMed

Insights

Genetic variants in calcium signaling genes, specifically the histidine-rich calcium-binding protein (HRC) Ser96Ala polymorphism, are linked to worse survival in heart failure patients. This finding may improve risk stratification for sudden cardiac death and implantable cardioverter-defibrillator (ICD) selection.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Sudden cardiac death (SCD) is a major concern in heart failure (HF) patients, often linked to arrhythmias caused by calcium handling alterations.
  • Genetic variations in calcium signaling pathways are associated with SCD risk.

Purpose of the Study:

  • To investigate the association of specific gene polymorphisms (HRC Ser96Ala, ADRB1 Ser49Gly, ADRB1 Arg389Gly, RYR2 Gly1886Ser) with serious arrhythmic events and mortality in non-ischemic HF patients with reduced ejection fraction.

Main Methods:

  • Retrospective cohort study of 136 HF patients.
  • Invasive electrophysiological study, physical examination, laboratory tests, and cardiac function assessment.
  • Follow-up for serious arrhythmic events (SCD or appropriate ICD therapy) and all-cause death.

Main Results:

  • The histidine-rich calcium-binding protein (HRC) Ser96Ala polymorphism's Ser allele was associated with poorer survival (log-rank P=0.043).
  • Beta-1 adrenergic receptor (ADRB1) Ser49Ser/Arg389Arg genotypes showed a trend towards increased mortality risk, but this was not statistically significant after covariate adjustment.
  • No association was found for the ryanodine receptor 2 (RYR2) Gly1886Ser polymorphism.

Conclusions:

  • The HRC Ser96Ala polymorphism may serve as a prognostic marker in HF patients, potentially aiding in risk stratification and guiding decisions for implantable cardioverter-defibrillator (ICD) implantation.
  • ADRB1 and RYR2 polymorphisms showed no significant association with outcomes in this cohort.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
129
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
94
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341